Skip to main content
padlock icon - secure page this page is secure

Open Access Personalised medicine for biliary tract and pancreatic cancers

Download Article:
 Download
(PDF 1,095.2 kb)
 
Associate Professor Yoshimasa Saito of Keio University, Japan, and Dr Gerda Egger of the Medical University of Vienna and Ludwig Boltzmann Institute Applied Diagnostics in Austria, have teamed up to continue their work into modelling and researching the molecular pathways of treatment-resistant biliary duct (cholangiocarcinoma) and pancreatic cancers.

The teams are taking a four-step process to research this area, with a view to identifying new therapies that can target individual cancers. The first step is to continue to culture organoid models of the cancers for study and drug screening. Secondly, a range of analyses will be undertaken on these models, by both teams, to identify stage-specific biomarkers of diseases. In the third stage, the identified molecular epigenomic and genetic biomarkers will be validated using CRISPR/Cas9 editing to develop disease models in organoids and mice. Lastly, these models and those developed from patients' own tumour samples will be used to screen drugs for personalised therapy.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: BILIARY TRACT CANCER; BIOMARKER; CHOLANGIOCARCINOMA; DRUG SCREENING; EPIGENETICS; MICRORNA; ORGANOID; PANCREATIC CANCER; PERSONALISED THERAPY

Document Type: Research Article

Publication date: October 15, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more